SCHEMBL10008763

SCHEMBL10008763

O=C(CCc1ccc(F)cc1)Nc1ncc(Cc2ccc(C(F)(F)F)cc2)s1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ LMNA P02545 4/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ NPC1 O15118 3/20 0.57
▸ RAB9A P51151 3/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ ALDH1A1 P00352 2/20 0.57
▸ HPGD P15428 2/20 0.57
▸ NFKB1 P19838 2/20 0.57
▸ NFKB2 Q00653 2/20 0.57
▸ RELA Q04206 2/20 0.57
▸ ABL1 P00519 5/20 0.56
▸ GPER1 Q99527 1/20 0.52
▸ ATM Q13315 1/20 0.50
▸ MAPT P10636 2/20 0.48
▸ SCD O00767 1/20 0.46
▸ JAK2 O60674 1/20 0.46
▸ ZAP70 P43403 1/20 0.46
▸ SYK P43405 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10008543 0.92 KMT2A (0.65) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10009298 0.91 LMNA (0.55) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10009261 0.85 ABL1 (0.50) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL16085538 0.85 LMNA (0.53) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10007869 0.85 NPC1 (0.57) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10010248 0.84 KMT2A (0.59) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10299109 0.84 MEN1 (0.59) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10008889 0.83 JAK2 (0.62) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10009184 0.82 NPC1 (0.56) MEN1KMT2ALMNASMN1; SMN2NPC1
SCHEMBL10009103 0.81 SCD (0.64) MEN1KMT2ALMNASMN1; SMN2ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883793-B2 Tubulin inhibitors and methods of using the same DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-11-11 — — US claimed
WO-2012092471-A2 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — WO claimed
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — US claimed
US-8883793-B2 Tubulin inhibitors and methods of using the same DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-11-11 — — US disclosed
US-8883793-B2 Tubulin inhibitors and methods of using the same DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2014-11-11 — — US disclosed
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — US disclosed
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — US disclosed
WO-2012092471-A2 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) 2012-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172374-A1 NOVEL TUBULIN INHIBITORS AND METHODS OF USING THE SAME TUBB1, TUBA1C, TUBB MEN1 740/4885KMT2A 1778/4885LMNA 1114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback